

## April 15, 2025

# **CPC Diagnostics Private Limited: Change in Limits**

# **Summary of rating action**

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating Action
Long-term Fund-based –Cash Credit	32.50	35.50	[ICRA]BBB+(Stable); Outstanding
Long-term Fund-based –Term Loan	9.00	5.85	[ICRA]BBB+(Stable); Outstanding
Short-term - Non-fund based - Sub-limit	(1.50)	(1.50)	[ICRA]A2; Outstanding
Long-term Fund-based –Overdraft	0.48	0.48	[ICRA]BBB+(Stable); Outstanding
Long-term - Unallocated	-	0.15	[ICRA]BBB+(Stable); Outstanding
Total	41.98	41.98	

<sup>\*</sup>Instrument details are provided in Annexure I

#### Rationale

This rationale is being released to convey the change in the rated limits as depicted in the table above, based on the latest information received from the entity.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their description, the liquidity position and rating sensitivities: <u>click here</u>

# **Analytical approach**

Analytical approach	Comments		
Applicable rating methodologies Corporate Credit Rating Methodology			
Parent/Group support	Not Applicable		
Consolidation/Standalone	The ratings are based on the company's standalone financial profile		

# **About the company**

CPC Diagnostics Private Limited is a provider of products and services to the clinical laboratory industry in India, Sri Lanka and Bangladesh. The promoters have been engaged in similar businesses since 1987. CPC has a technical collaboration with AL SYSTEME, Germany, to manufacture haematology analysers in India through its manufacturing arm, CPC Medical Systemz. The company sells reagents and instruments, mostly imported from Germany, China, Japan and the US, along with some indigenously manufactured products from its facility in Porur, Chennai. CPC offers a spectrum of instruments and reagents in clinical chemistry, hematology, and coagulation and immunodiagnostic.

# **Key financial indicators (audited)**

CPC (consolidated)	FY2023	FY2024	9MFY2025*
Operating income	194.9	248.1	224.3
PAT	11.5	8.8	17.8
OPBDIT/OI	14.8%	16.2%	16.9%
PAT/OI	5.9%	3.5%	7.9%
Total outside liabilities/Tangible net worth (times)	0.7	0.6	0.6
Total debt/OPBDIT (times)	0.7	0.6	0.7
Interest coverage (times)	10.4	13.2	15.0

www.icra.in



Source: Company, ICRA Research; \* Provisional numbers; All ratios as per ICRA's calculations; Amount in Rs. crore PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

# Status of non-cooperation with previous CRA: Not applicable

# Any other information: None

# Rating history for past three years

Current rating (FY2026)					Chronology of rating history for the past 3 years						
					FY2026		FY2025		FY2024		FY2023
Instrument	Туре	Amount Rated (Rs Crore)	Apr 15, 2025	Date	Rating	Date	Rating	Date	Rating	Date	Rating
Long term- overdraft-fund based	Long Term	0.48	[ICRA]BBB+ (Stable)	-	-	Mar 28, 2025	[ICRA]BBB+ (Stable)	Mar 21, 2024	[ICRA]BBB+ (Stable)	Dec 26, 2022	[ICRA]BBB (Stable)
Long term-cash credit-fund based	Long Term	35.50	[ICRA]BBB+ (Stable)	-	-	Mar 28, 2025	[ICRA]BBB+ (Stable)	Mar 21, 2024	[ICRA]BBB+ (Stable)	Dec 26, 2022	[ICRA]BBB (Stable)
Long term-term loan-fund based	Long Term	5.85	[ICRA]BBB+ (Stable)	-	-	Mar 28, 2025	[ICRA]BBB+ (Stable)	Mar 21, 2024	[ICRA]BBB+ (Stable)	Dec 26, 2022	[ICRA]BBB (Stable)
Short term- others- interchangeable	Short Term	1.50	[ICRA]A2	-	-	Mar 28, 2025	[ICRA]A2	Mar 21, 2024	[ICRA]A2	Dec 26, 2022	[ICRA]A3+
Long term - Unallocated	Long Term	0.15	[ICRA]BBB+ (Stable)	-	-	-	-	-	-	-	-

# **Complexity level of the rated instruments**

Instrument	Complexity indicator
Long-term Fund-based – Cash Credit	Simple
Long-term Fund-based – Term Loan	Simple
Non-fund based sublimit	Very Simple
Long-term Fund-based –Overdraft	Simple
Long-term - Unallocated	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: Click here

www.icra.in Page | 2



## **Annexure I: Instrument details**

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Cash Credit	-	NA	-	35.50	[ICRA]BBB+(Stable)
NA	Term Loan	April 2022	NA	October 2027	5.85	[ICRA]BBB+ (Stable)
NA	Non-fund-based facility – Sub-limit	-	NA	-	(1.50)	[ICRA]A2
NA	Overdraft	-	NA	-	0.48	[ICRA]BBB+ (Stable)
NA	Unallocated Limits				0.15	[ICRA]BBB+ (Stable)

Source: Company

Please click here to view details of lender-wise facilities rated by ICRA

Annexure II: List of entities considered for consolidated analysis – Not Applicable

www.icra.in Page | 3



### **ANALYST CONTACTS**

Jitin Makkar +91 124 4545368 jitinm@icraindia.com

Nithya Debbadi +91 40 6939 6416 nithya.debbadi@icraindia.com Srikumar K +91 44 4596 4318 ksrikumar@icraindia.com

Raviteja Etikala +9140 6939 6418 etikala.teja@icraindia.com

#### **RELATIONSHIP CONTACT**

L. Shivakumar +91 22 6114 3406 shivakumar@icraindia.com

#### MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

### **HELPLINE FOR BUSINESS QUERIES**

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

#### **ABOUT ICRA LIMITED**

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in



# **ICRA Limited**



# **Registered Office**

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001 Tel: +91 11 23357940-45



# © Copyright, 2025 ICRA Limited. All Rights Reserved.

# Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.